Literature DB >> 30378450

Chronic kidney disease, cardiovascular disease, and osteoporotic fractures in patients with and without HIV in the US Veteran's Affairs Administration System.

S S Sutton1,2, J Magagnoli2, T H Cummings2, J W Hardin3, B Edun2, A Beaubrun4.   

Abstract

Objective: To evaluate the risk of chronic kidney disease (CKD), cardiovascular disease (CVD), and osteoporotic fractures in human immunodeficiency virus (HIV) patients utilizing data within the Veteran's Affairs (VA) Administration system.
Methods: A retrospective cohort study utilizing VA system claims (January 2000-December 2016) were extracted from the VA Informatics and Computing Infrastructure (VINCI). Cases included Veterans with an ICD-9/10 for HIV who had at least one prescription for a complete antiretroviral therapy (ART) regimen. Two non-HIV controls were exactly matched on race, sex, month, and year of birth. All patients were followed until the earliest of the following: first incidence of the outcome (identified based on diagnosis codes or laboratory data), last date of VA activity, death, or December 31, 2016. Relative risks (RR) and odds ratios (ORs) were estimated from multivariable Poisson regression models (CVD and osteoporotic fractures) and multivariable logistic regression models (CKD), respectively. Models were adjusted for demographic factors/comorbidities.
Results: A total of 79,578 patients (26,526 HIV and 53,052 non-HIV) met all study criteria. The average age was 49.3 years, 38% were black, 32% were white, and 97% were male for both the HIV and control cohorts. The adjusted models demonstrated that HIV was associated with a 78% increased rate of CKD (OR = 1.78, 95% CI = 1.68-1.89), a 32% increased risk of CVD (RR = 1.32, 95% CI = 1.28-1.37), and a 38% increased risk of fractures (RR = 1.38, 95% CI = 1.23-1.56) compared to non-HIV controls.Conclusions: The risk/rate of the three outcomes were significantly higher in HIV patients compared to controls.

Entities:  

Keywords:  Antiretroviral therapy; Cardiovascular disease; Chronic kidney disease; HIV; Osteoporotic fractures; Veteran affairs informatics and computing infrastructure

Mesh:

Year:  2018        PMID: 30378450     DOI: 10.1080/03007995.2018.1543183

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  5 in total

Review 1.  SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment.

Authors:  Julia Del Amo; Rosa Polo; Santiago Moreno; Inma Jarrín; Miguel A Hernán
Journal:  AIDS       Date:  2022-02-01       Impact factor: 4.177

2.  Association Between CD4/CD8 Ratio Recovery and Chronic Kidney Disease Among Human Immunodeficiency Virus-Infected Patients Receiving Antiretroviral Therapy: A 17-Year Observational Cohort Study.

Authors:  Fengxiang Qin; Qing Lv; Wen Hong; Di Wei; Kui Huang; Ke Lan; Rongfeng Chen; Jie Liu; Bingyu Liang; Huayue Liang; Hao Liang; Shanfang Qin; Li Ye; Junjun Jiang
Journal:  Front Microbiol       Date:  2022-02-10       Impact factor: 5.640

3.  Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy.

Authors:  Leonardo Calza; Michele Sachs; Vincenzo Colangeli; Marco Borderi; Bianca Granozzi; Pietro Malosso; Giorgia Comai; Valeria Corradetti; Gaetano La Manna; Pierluigi Viale
Journal:  Clin Exp Nephrol       Date:  2019-07-20       Impact factor: 2.801

4.  Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study.

Authors:  Ni Gusti Ayu Nanditha; Adrianna Paiero; Hiwot M Tafessu; Martin St-Jean; Taylor McLinden; Amy C Justice; Jacek Kopec; Julio S G Montaner; Robert S Hogg; Viviane D Lima
Journal:  BMJ Open       Date:  2021-01-08       Impact factor: 3.006

5.  VCAM-1 as a Biomarker of Endothelial Function among HIV-Infected Patients Receiving and Not Receiving Antiretroviral Therapy.

Authors:  Agnieszka Lembas; Katarzyna Zawartko; Mariusz Sapuła; Tomasz Mikuła; Joanna Kozłowska; Alicja Wiercińska-Drapało
Journal:  Viruses       Date:  2022-03-11       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.